Figitumumab
- Generic Name
- Figitumumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 943453-46-1
- Unique Ingredient Identifier
- VE267FC2UB
- Background
Figitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2013-02-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT00977561
- Locations
- 🇪🇸
Pfizer Investigational Site, Valencia, Spain
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2013-12-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00976508
- Locations
- 🇩🇪
Pfizer Investigational Site, Muenster, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath